Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Therapy

Trial Profile

A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2019

At a glance

  • Drugs Insulin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Oramed Pharmaceuticals
  • Most Recent Events

    • 15 Jan 2019 According to an Oramed Pharmaceuticals media release, the company has exceeded 75% randomization in this trial. This trial is expected to complete in 2019 and results are expected in Q4 2019.
    • 06 Dec 2018 Planned number of patients changed from 240 to 265.
    • 13 Nov 2018 According to an Oramed Pharmaceuticals media release, 50% of the expected 285 patients have been randomized successfully. Data release is expected in the coming year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top